Loboplatin in advanced urothelial tract tumors
| Autor: | P.H.M. de Mulder, S. Daamen, Stan B. Kaye, Cora N. Sternberg, A. Pawinsky, Timothy T. Roberts, Sophie D. Fosså |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Cisplatin
medicine.medical_specialty Pathology Chemotherapy Bladder cancer Urinary bladder business.industry medicine.medical_treatment Urology Phases of clinical research Cancer Hematology medicine.disease Lobaplatin Transitional cell carcinoma medicine.anatomical_structure Oncology Immunogenecity of the renal cell carcinoma antigen G250 medicine business medicine.drug |
| Zdroj: | Annals of Oncology, 8, pp. 695-696 Annals of Oncology, 8, 695-696 |
| ISSN: | 0923-7534 |
| DOI: | 10.1023/a:1008269432176 |
| Popis: | Bladder cancer is the fifth most common cancer in men and the seventh in women. Combination regimens containing cisplatin have produced response rates in 50%70% of patients with complete responses in 20%-30% [1]. Lobaplatin (1,2-diamminomethylcyclobutane-platinum (II) lactate, D-19466) is a third generation platinum analogue. It is water soluble and stable and may not be cross-resistant with cisplatin [2, 3]. A favorable toxicity profile and similar efficacy to cisplatin stimulated a phase II study in patients with advanced urothelial tract tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|